Dried Blood Spot (DBS) Testing: A Safe and Simple Solution for Infectious Disease Screening

Infectious disease screening is a cornerstone of global and community health, yet traditional sample collection methods can be logistically complex and hazardous to handle. Dried blood spot (DBS) testing offers an often transformative alternative. With just a few drops of blood collected from a finger prick, DBS enables safe, simple, and scalable diagnostics, especially in resource-limited or remote settings.

A significant yet often overlooked advantage of DBS testing is: once blood samples have dried, the sample is no longer infectious. This dramatically reduces the risk to those handling, storing, or transporting the sample and makes DBS an ideal method for infectious disease surveillance worldwide. Let’s explore how dried blood tests work, why they are often safer than venous draws, and which areas already benefit from DBS testing.

How DBS Testing Works

DBS collection is straightforward. A lancet is used to prick the finger, and drops of blood are applied to a specially designed filter paper card. Once the sample has dried thoroughly, it is sealed in protective packaging and sent to a laboratory for analysis and subsequent delivery of testing results. The simplicity of this method eliminates the need for phlebotomists, cold-chain logistics, or fragile glass tubes.

Why Dried Samples Are Safer

Unlike serologic tests using liquid blood specimens, dried blood poses a negligible risk of pathogen transmission. This is a critical factor in large-scale screening efforts or in regions dealing with infectious outbreaks. Benefits of non-infectious dried samples include:

  • Safe handling for lab technicians, couriers, and healthcare workers
  • Reduced need for biohazard protocols during storage and transport
  • Minimized risk of cross-contamination during sample collection and processing

In outbreak zones or high-prevalence areas, DBS offers a secure way to collect biological data without increasing exposure risks.

Infectious Diseases Effectively Screened with DBS

Dried blood spot samples can be used to screen for a wide range of infectious diseases, including:

  • HIV (antibody testing and viral load monitoring)
  • Hepatitis B and C
  • Syphilis and other STIs
  • COVID-19 antibodies
  • Malaria (via antigen or antibody detection)
  • Emerging diseases like dengue or Zika

Some programs even perform multiplex testing on a single DBS card, analyzing multiple infections from one small sample.

Practical Benefits for Global and Local Screening Programs

DBS is uniquely positioned to serve the needs of global health initiatives, public health programs, and decentralized care models. Key advantages include:

  • No refrigeration required, enabling mail-in or field-based collection
  • Low training threshold, empowering non-clinical staff and volunteers to assist with screening
  • High scalability for population surveillance, outbreak response, and epidemiological studies
  • Enhanced access for hard-to-reach or underserved populations

From mobile testing units to public health campaigns, DBS helps bring diagnostic capacity closer to where it’s needed most.

Accuracy and Reliability of DBS Testing

Modern laboratories use validated methods like ELISA and PCR adapted specifically for dried matrices. Numerous studies have demonstrated that DBS can offer sensitivity and specificity comparable to venous blood for many infectious disease tests.

Additionally, dried samples are more stable during transit and less prone to logistical errors (e.g., hemolysis, leakage, or sample degradation), reducing rejection rates and improving turnaround times.

Real-World Applications and Public Health Use Cases

DBS is already being used in:

  • National HIV surveillance programs in sub-Saharan Africa
  • Hepatitis screening in high-risk populations
  • At-home STI testing kits
  • NGO-led malaria research in rural Southeast Asia
  • COVID-19 antibody studies conducted through mail-in kits

Its adaptability makes it valuable for both acute outbreak management and long-term epidemiological tracking of communicable diseases.

RDA Spot’s Commitment to Safe and Scalable Sample Collection

At RDA Spot, we believe that sample quality drives diagnostic confidence. Our DBS kits are engineered to support infectious disease screening from the ground up:

  • Safe to handle, even during disease outbreaks
  • Lab-compatible, with materials validated for stability and accuracy
  • Field-ready, supporting health workers in both urban and rural environments

With roots in scientific rigor and a mission to expand access to diagnostic tools, RDA Spot partners with labs, health systems, and public health programs to ensure the success of DBS-based initiatives. We help bridge the gap between innovative microsampling and real-world impact.

Interested in DBS Testing Solutions?

Dried blood spot testing offers a safe, simple, and scalable solution to infectious disease screening. By eliminating the hazards of handling liquid blood and simplifying logistics, DBS empowers healthcare providers and public health workers to expand testing into places and populations that need it most.

As trusted partners in this mission, RDA Spot continues to advance the tools and standards that make high-quality DBS testing possible; helping shape a healthier, more accessible future for all.

References

  1. Tuaillon E, et al. Dried Blood Spot Tests for the Diagnosis and Therapeutic Monitoring of HIV and Viral Hepatitis B and C. Frontiers in Microbiology. Vol 11. 2020. DOI: 10.3389/fmicb.2020.00373.
  2. Kulkarni S, et al. Assessment of the suitability of the dried blood spot (DBS) samples for detection of Treponemal antibodies using in vitro assays. Indian J Med Res. 2025. DOI: 10.25259/IJMR_1195_2024.
  3. Maheu-Giroux M, et al. National HIV testing and diagnosis coverage in sub-Saharan Africa: a new modeling tool for estimating the ‘first 90’ from program and survey data. AIDS. 2019. DOI: 10.1097/QAD.0000000000002386.
  4. O’Flaherty K, et al. Community-based molecular and serological surveillance of subclinical malaria in Myanmar. BMC Med. 2021. DOI: 10.1186/s12916-021-01993-8.